According to a post on the FDA’s website, Poseida Therapeutics’ treatment of multiple myeloma received orphan designation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PSTX:
- 3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts
- Poseida Therapeutics Announces Executive Leadership Change
- Poseida Therapeutics reports Q4 EPS (27c), consensus (39c)
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
- PSTX Earnings this Week: How Will it Perform?
